{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:11:35Z","timestamp":1779275495108,"version":"3.51.4"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:p>\n                    Myasthenia gravis (MG), an autoimmune condition known for impairing neuromuscular signaling, has increasingly been implicated in broader neurological dysfunctions. Recent studies point toward a possible connection between autoimmune and neurodegenerative processes. However, whether MG contributes causally to the onset of major neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) remains unclear. This study utilizes Mendelian randomization (MR) to explore the potential causal influence of MG on these disorders from a genetic standpoint. A univariable Mendelian randomization (UVMR) framework was employed using summary-level data from genome-wide association studies (GWAS) to evaluate the effect of MG on the risk of AD, PD, and ALS. To confirm the robustness of the association between MG and AD, 2 independent AD GWAS datasets were incorporated for external replication, followed by a meta-analysis to combine the evidence. Additionally, multivariable Mendelian randomization (MVMR) was conducted to adjust for smoking behavior as a potential confounding factor. The UVMR analysis revealed a statistically significant causal relationship between MG and increased susceptibility to AD (odds ratio (OR): 1.037; 95% confidence interval (CI): 1.007\u20131.068;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.016). No significant causal effects were observed for PD (OR: 1.019; 95% CI: 0.964\u20131.077;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.509) or ALS (OR: 1.055; 95% CI: 0.977\u20131.140;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.171). The association between MG and AD was consistently validated in 2 independent datasets (ieu-a-297: OR\u2005=\u20051.084; 95% CI: 1.017\u20131.156;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.013; ieu-b-2: OR\u2005=\u20051.054; 95% CI: 1.006\u20131.104;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.027). Meta-analysis reinforced the evidence supporting MG as a risk factor for AD (OR: 1.047; 95% CI: 1.023\u20131.072;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Furthermore, MVMR adjusting for smoking confirmed that MG independently contributes to AD risk (OR: 1.037; 95% CI: 1.006\u20131.069;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.020). This study provides robust genetic evidence suggesting that MG is a causal and independent risk factor for AD. These findings highlight a novel link between autoimmunity and neurodegeneration, offering new directions for mechanistic and therapeutic research.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045340","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:01:30Z","timestamp":1763571690000},"page":"e45340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the potential causal influence of myasthenia gravis on neurodegenerative diseases via multivariable Mendelian randomization"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8065-9653","authenticated-orcid":false,"given":"Xingwang","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery, The First Hospital of Nanchang, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, The First Hospital of Nanchang, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update.","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"e179742","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here.","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Investig"},{"key":"R3-20260520","doi-asserted-by":"crossref","first-page":"e16229","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment.","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"103104","DOI":"10.1016\/j.autrev.2022.103104","article-title":"Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.","volume":"21","author":"Man\u00e9-Damas","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"1502480","DOI":"10.3389\/fimmu.2024.1502480","article-title":"A clinical perspective on muscle specific kinase antibody positive myasthenia gravis.","volume":"15","author":"Keritam","year":"2024","journal-title":"Front Immunol"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase.","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.25386","article-title":"Assessment of physical fatigability and fatigue perception in myasthenia gravis.","volume":"55","author":"Jordan","year":"2017","journal-title":"Muscle Nerve"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mus.26356","article-title":"Muscle weakness and functional disability in patients with myasthenia gravis.","volume":"59","author":"Vinge","year":"2019","journal-title":"Muscle Nerve"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00415-019-09461-3","article-title":"Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.","volume":"266","author":"Kimura","year":"2019","journal-title":"J Neurol"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2011.200","article-title":"Myasthenia gravis\u2013associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?","volume":"68","author":"Vaknin-Dembinsky","year":"2011","journal-title":"Arch Neurol"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","article-title":"Neurodegenerative disease: models, mechanisms, and a new hope.","volume":"10","author":"Gitler","year":"2017","journal-title":"Dis Models Mech"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/ene.13972","article-title":"Burden of neurodegenerative diseases in the Eastern Mediterranean Region, 1990\u20132016: findings from the Global Burden of Disease Study 2016.","volume":"26","author":"Fereshtehnejad","year":"2019","journal-title":"Eur J Neurol"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis.","volume":"390","author":"Van Es","year":"2017","journal-title":"Lancet (London, England)"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review.","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.25373","article-title":"Parkinson\u2019s disease and alpha synuclein: is Parkinson\u2019s disease a prion\u2010like disorder?","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov Dis"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-021-04199-3","article-title":"Structure of pathological TDP-43 filaments from ALS with FTLD.","volume":"601","author":"Arseni","year":"2022","journal-title":"Nature"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"10809","DOI":"10.3390\/ijms241310809","article-title":"Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and amyotrophic lateral sclerosis.","volume":"24","author":"Ciurea","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R18-20260520","doi-asserted-by":"crossref","first-page":"12495","DOI":"10.3390\/ijerph191912495","article-title":"Neurodegenerative diseases: implications of environmental and climatic influences on neurotransmitters and neuronal hormones activities.","volume":"19","author":"Ayeni","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R19-20260520","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nri3705","article-title":"Innate immune activation in neurodegenerative disease.","volume":"14","author":"Heneka","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R20-20260520","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"R21-20260520","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials.","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R22-20260520","first-page":"504","article-title":"Oxidative stress in neurodegenerative diseases.","volume":"11","author":"Domanskyi","year":"2022","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"R23-20260520","doi-asserted-by":"crossref","first-page":"837579","DOI":"10.3389\/ftox.2022.837579","article-title":"Role of environmental toxicants on neurodegenerative disorders.","volume":"4","author":"Nabi","year":"2022","journal-title":"Front Toxicol"},{"key":"R24-20260520","doi-asserted-by":"crossref","first-page":"691136","DOI":"10.3389\/fncel.2021.691136","article-title":"Microbial infections are a risk factor for neurodegenerative diseases.","volume":"15","author":"Lotz","year":"2021","journal-title":"Front Cell Neurosci"},{"key":"R25-20260520","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2019.03.016","article-title":"Immune signaling in neurodegeneration.","volume":"50","author":"Hammond","year":"2019","journal-title":"Immunity"},{"key":"R26-20260520","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000369933","article-title":"Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases.","volume":"15","author":"Fakhoury","year":"2015","journal-title":"Neurodegen Dis"},{"key":"R27-20260520","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2567.2009.03225.x","article-title":"Inflammation in neurodegenerative diseases.","volume":"129","author":"Amor","year":"2010","journal-title":"Immunology"},{"key":"R28-20260520","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrneurol.2010.17","article-title":"Microglia in neurodegenerative disease.","volume":"6","author":"Perry","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R29-20260520","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12974-022-02605-9","article-title":"The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases.","volume":"19","author":"DeMaio","year":"2022","journal-title":"J Neuroinflammation"},{"key":"R30-20260520","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jb\/mvw009","article-title":"Microglia in central nervous system repair after injury.","volume":"159","author":"Jin","year":"2016","journal-title":"J Biochem"},{"key":"R31-20260520","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets.","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Trans Target Ther"},{"key":"R32-20260520","doi-asserted-by":"crossref","first-page":"578180","DOI":"10.1016\/j.jneuroim.2023.578180","article-title":"Microglia mediated neuroinflammation in neurodegenerative diseases: a review on the cell signaling pathways involved in microglial activation.","volume":"383","author":"Biswas","year":"2023","journal-title":"J Neuroimmunol"},{"key":"R33-20260520","doi-asserted-by":"crossref","first-page":"41","DOI":"10.33588\/rn.7802.2023120","article-title":"Miastenia gravis y enfermedad de Alzheimer: una asociaci\u00f3n a estudio.","volume":"78","author":"Morales-Casado","year":"2024","journal-title":"Rev Neurol"},{"key":"R34-20260520","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.parkreldis.2021.06.016","article-title":"Coincident parkinsonism and myasthenia gravis: a case series.","volume":"89","author":"Alshaikh","year":"2021","journal-title":"Parkinsonism Related Disorders"},{"key":"R35-20260520","doi-asserted-by":"crossref","first-page":"1303434","DOI":"10.3389\/fneur.2023.1303434","article-title":"Parkinson\u2019s disease and comorbid myasthenia gravis: a case report and literature review.","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Neurol"},{"key":"R36-20260520","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13760-022-01894-4","article-title":"Myasthenia gravis with amyotrophic lateral sclerosis with positive anti-Hu antibody: a rare co-existence.","volume":"123","author":"Sun","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"R37-20260520","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00401-010-0722-x","article-title":"Contribution of systemic inflammation to chronic neurodegeneration.","volume":"120","author":"Perry","year":"2010","journal-title":"Acta Neuropathol"},{"key":"R38-20260520","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease.","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"R39-20260520","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2174\/1871527313666140917121132","article-title":"Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?","volume":"13","author":"Tata","year":"2014","journal-title":"CNS Neurol Disorders Drug Targets"},{"key":"R40-20260520","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2023.4115","article-title":"Mendelian randomization as a tool for cardiovascular research: a review.","volume":"9","author":"Levin","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R41-20260520","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in Mendelian randomization studies.","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"R42-20260520","doi-asserted-by":"crossref","first-page":"1370831","DOI":"10.3389\/fimmu.2024.1370831","article-title":"Investigation of the causal association between Parkinson\u2019s disease and autoimmune disorders: a bidirectional Mendelian randomization study.","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"R43-20260520","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/aje\/kwr323","article-title":"Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions.","volume":"175","author":"Glymour","year":"2012","journal-title":"Am J Epidemiol"},{"key":"R44-20260520","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res"},{"key":"R45-20260520","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12916-023-02894-8","article-title":"Standardizing the reporting of Mendelian randomization studies.","volume":"21","author":"Au Yeung","year":"2023","journal-title":"BMC Med"},{"key":"R46-20260520","article-title":"The MRC IEU OpenGWAS data infrastructure.","author":"Elsworth","year":"2020","journal-title":"BioRxiv"},{"key":"R47-20260520","doi-asserted-by":"crossref","first-page":"1199896","DOI":"10.3389\/fimmu.2023.1199896","article-title":"Association between systemic lupus erythematosus and inflammatory bowel disease in European and East Asian populations: a two-sample Mendelian randomization study.","volume":"14","author":"Xie","year":"2023","journal-title":"Front Immunol"},{"key":"R48-20260520","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"R49-20260520","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/gepi.22385","article-title":"Caution against examining the role of reverse causality in Mendelian randomization.","volume":"45","author":"Lutz","year":"2021","journal-title":"Genet Epidemiol"},{"key":"R50-20260520","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data.","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"R51-20260520","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method.","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"R52-20260520","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator.","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R53-20260520","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/ije\/dyab084","article-title":"The use of two-sample methods for Mendelian randomization analyses on single large datasets.","volume":"50","author":"Minelli","year":"2021","journal-title":"Int J Epidemiol"},{"key":"R54-20260520","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1002\/sim.9156","article-title":"Pleiotropy robust methods for multivariable Mendelian randomization.","volume":"40","author":"Grant","year":"2021","journal-title":"Stat Med"},{"key":"R55-20260520","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s11481-020-09908-9","article-title":"Immune and inflammatory determinants underlying Alzheimer\u2019s disease pathology.","volume":"15","author":"Baulch","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"R56-20260520","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis \u2013 autoantibody characteristics and their implications for therapy.","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"R57-20260520","doi-asserted-by":"crossref","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management.","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol"},{"key":"R58-20260520","doi-asserted-by":"crossref","first-page":"e183597","DOI":"10.1001\/jamanetworkopen.2018.3597","article-title":"Association of chronic low-grade inflammation with risk of Alzheimer disease in ApoE4 carriers.","volume":"1","author":"Tao","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R59-20260520","doi-asserted-by":"crossref","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis.","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci Rep"},{"key":"R60-20260520","doi-asserted-by":"crossref","first-page":"39716","DOI":"10.1038\/srep39716","article-title":"Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients.","volume":"7","author":"Molin","year":"2017","journal-title":"Sci Rep"},{"key":"R61-20260520","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"R62-20260520","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: targeting the cholinergic system.","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"R63-20260520","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jneuroim.2008.05.022","article-title":"Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia gravis and neuroinflammation.","volume":"201-202","author":"Brenner","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R64-20260520","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/aje\/kwj062","article-title":"Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials.","volume":"163","author":"Nitsch","year":"2006","journal-title":"Am J Epidemiol"},{"key":"R65-20260520","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/path.5421","article-title":"The use of Mendelian randomisation to identify causal cancer risk factors: promise and limitations.","volume":"250","author":"Gala","year":"2020","journal-title":"J Pathol"},{"key":"R66-20260520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: prospects, potentials, and limitations.","volume":"33","author":"Smith","year":"2004","journal-title":"Int J Epidemiol"},{"key":"R67-20260520","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/cer.13.14","article-title":"Using Mendelian randomization to assess and develop clinical interventions: limitations and benefits.","volume":"2","author":"Burgess","year":"2013","journal-title":"J Comp Eff Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:01:35Z","timestamp":1779274895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":67,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045340","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}